| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Improved survival with ipilimumab in patients with metastatic melanoma.
|
N Engl J Med
|
2010
|
67.34
|
|
2
|
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
|
N Engl J Med
|
2015
|
14.71
|
|
3
|
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations.
|
N Engl J Med
|
2012
|
13.48
|
|
4
|
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.
|
N Engl J Med
|
2012
|
13.17
|
|
5
|
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.
|
N Engl J Med
|
2012
|
6.93
|
|
6
|
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
|
J Clin Oncol
|
2009
|
6.44
|
|
7
|
gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.
|
N Engl J Med
|
2011
|
5.15
|
|
8
|
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.
|
Lancet Oncol
|
2012
|
4.19
|
|
9
|
Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma.
|
J Clin Oncol
|
2009
|
3.80
|
|
10
|
Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group.
|
J Clin Oncol
|
2008
|
3.58
|
|
11
|
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.
|
J Clin Oncol
|
2013
|
2.51
|
|
12
|
Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor.
|
J Clin Oncol
|
2012
|
2.45
|
|
13
|
Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma.
|
J Clin Oncol
|
2002
|
2.26
|
|
14
|
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
|
J Clin Oncol
|
2013
|
2.11
|
|
15
|
Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.
|
Clin Cancer Res
|
2006
|
1.72
|
|
16
|
ALDH1A isozymes are markers of human melanoma stem cells and potential therapeutic targets.
|
Stem Cells
|
2012
|
1.70
|
|
17
|
Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients.
|
Ann Surg Oncol
|
2007
|
1.69
|
|
18
|
A single-arm, open-label, expanded access study of vemurafenib in patients with metastatic melanoma in the United States.
|
Cancer J
|
2014
|
1.51
|
|
19
|
Long-term follow-up and survival of patients following a recurrence of melanoma after a negative sentinel lymph node biopsy result.
|
JAMA Surg
|
2013
|
1.50
|
|
20
|
A multi-center phase II evaluation of the small molecule survivin suppressor YM155 in patients with unresectable stage III or IV melanoma.
|
Invest New Drugs
|
2009
|
1.47
|
|
21
|
The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
|
Nat Rev Clin Oncol
|
2013
|
1.46
|
|
22
|
Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control.
|
Radiat Oncol
|
2011
|
1.46
|
|
23
|
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial.
|
J Clin Oncol
|
2005
|
1.37
|
|
24
|
Metastatic melanoma in the breast: a report of 27 cases.
|
J Surg Oncol
|
2006
|
1.31
|
|
25
|
A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma.
|
Cancer
|
2010
|
1.24
|
|
26
|
Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.
|
Clin Cancer Res
|
2010
|
1.19
|
|
27
|
Side population cells from human melanoma tumors reveal diverse mechanisms for chemoresistance.
|
J Invest Dermatol
|
2012
|
1.12
|
|
28
|
Severe paraneoplastic hypoglycemia in a patient with a gastrointestinal stromal tumor with an exon 9 mutation: a case report.
|
BMC Cancer
|
2007
|
1.11
|
|
29
|
A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma.
|
Invest New Drugs
|
2007
|
1.09
|
|
30
|
Survival in sentinel lymph node-positive pediatric melanoma.
|
J Pediatr Surg
|
2005
|
1.08
|
|
31
|
Melanoma, version 4.2014.
|
J Natl Compr Canc Netw
|
2014
|
1.07
|
|
32
|
A randomized phase 2 study of etaracizumab, a monoclonal antibody against integrin alpha(v)beta(3), + or - dacarbazine in patients with stage IV metastatic melanoma.
|
Cancer
|
2010
|
1.06
|
|
33
|
Phase II multicenter study of neoadjuvant biochemotherapy for patients with stage III malignant melanoma.
|
J Clin Oncol
|
2006
|
1.03
|
|
34
|
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology.
|
J Natl Compr Canc Netw
|
2016
|
1.02
|
|
35
|
Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.
|
J Clin Oncol
|
2009
|
1.01
|
|
36
|
PI-88: a novel inhibitor of angiogenesis.
|
Expert Opin Investig Drugs
|
2008
|
0.99
|
|
37
|
Identifying risk factors for complications following sentinel lymph node biopsy for melanoma.
|
Arch Surg
|
2005
|
0.98
|
|
38
|
Phase II, randomized, controlled, double-blinded trial of weekly elesclomol plus paclitaxel versus paclitaxel alone for stage IV metastatic melanoma.
|
J Clin Oncol
|
2009
|
0.97
|
|
39
|
Sentinel lymph node biopsy for melanoma and other melanocytic tumors in adolescents.
|
J Pediatr Surg
|
2005
|
0.97
|
|
40
|
A phase 2 study of high-dose Allovectin-7 in patients with advanced metastatic melanoma.
|
Melanoma Res
|
2010
|
0.94
|
|
41
|
A phase II study of neoadjuvant biochemotherapy for stage III melanoma.
|
Cancer
|
2002
|
0.94
|
|
42
|
Advances in the treatment of Basal cell carcinoma: Hedgehog inhibitors.
|
Semin Oncol
|
2012
|
0.90
|
|
43
|
ABT-737 synergizes with Bortezomib to kill melanoma cells.
|
Biol Open
|
2011
|
0.88
|
|
44
|
Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion.
|
J Transl Med
|
2012
|
0.87
|
|
45
|
Therapeutic options in cutaneous melanoma: latest developments.
|
Ther Adv Med Oncol
|
2011
|
0.87
|
|
46
|
Metastatic malignant melanoma from an unknown primary presenting as a large axillary mass.
|
Oncology (Williston Park)
|
2006
|
0.86
|
|
47
|
A review of novel therapies for melanoma.
|
Am J Clin Dermatol
|
2014
|
0.86
|
|
48
|
Efficacy and safety of HLA-B7/beta-2 microglobulin plasmid DNA/lipid complex (Allovectin-7) in patients with metastatic melanoma.
|
Expert Opin Biol Ther
|
2003
|
0.85
|
|
49
|
Low-dose outpatient chemobiotherapy with temozolomide, granulocyte-macrophage colony stimulating factor, interferon-alpha2b, and recombinant interleukin-2 for the treatment of metastatic melanoma.
|
J Clin Oncol
|
2005
|
0.85
|
|
50
|
Correlation between early 18F-FDG PET/CT response to BRAF and MEK inhibition and survival in patients with BRAF-mutant metastatic melanoma.
|
Nucl Med Commun
|
2016
|
0.84
|
|
51
|
Increased survival from stage IV melanoma associated with fewer regulatory T Cells.
|
J Surg Res
|
2008
|
0.84
|
|
52
|
A phase 1-2 study of imexon plus dacarbazine in patients with unresectable metastatic melanoma.
|
Cancer
|
2010
|
0.83
|
|
53
|
A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.
|
Invest New Drugs
|
2006
|
0.83
|
|
54
|
Phase I trial of ALT-801, an interleukin-2/T-cell receptor fusion protein targeting p53 (aa264-272)/HLA-A*0201 complex, in patients with advanced malignancies.
|
Clin Cancer Res
|
2011
|
0.83
|
|
55
|
Size of sentinel node metastases predicts other nodal disease and survival in malignant melanoma.
|
Am J Surg
|
2006
|
0.83
|
|
56
|
Lymphangiomatosis masquerading as metastatic melanoma.
|
Am Surg
|
2006
|
0.83
|
|
57
|
A randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrence.
|
Melanoma Res
|
2009
|
0.83
|
|
58
|
Novel therapies in melanoma.
|
Immunotherapy
|
2011
|
0.82
|
|
59
|
A phase 2 study of tasisulam sodium (LY573636 sodium) as second-line treatment for patients with unresectable or metastatic melanoma.
|
Cancer
|
2011
|
0.80
|
|
60
|
A neoadjuvant biochemotherapy approach to stage III melanoma: analysis of surgical outcomes.
|
Immunotherapy
|
2012
|
0.80
|
|
61
|
A phase II study of biochemotherapy for advanced melanoma incorporating temozolomide, decrescendo interleukin-2 and GM-CSF.
|
Cancer Invest
|
2005
|
0.80
|
|
62
|
New targeted therapies in melanoma.
|
Cancer Control
|
2013
|
0.79
|
|
63
|
Immunologic therapy targeting metastatic melanoma: allovectin-7.
|
Immunotherapy
|
2011
|
0.78
|
|
64
|
Metabolic response by FDG-PET to imatinib correlates with exon 11 KIT mutation and predicts outcome in patients with mucosal melanoma.
|
Cancer Imaging
|
2014
|
0.78
|
|
65
|
Anti-CTLA4 antibody therapy related complications on FDG PET/CT.
|
Clin Nucl Med
|
2014
|
0.77
|
|
66
|
Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature.
|
Int J Dermatol
|
2009
|
0.76
|
|
67
|
Pegylated interferon alpha-2b as adjuvant treatment of Stage III malignant melanoma: an evidence-based review.
|
Core Evid
|
2010
|
0.75
|
|
68
|
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
|
Melanoma Res
|
2017
|
0.75
|
|
69
|
The absent-minded professor: an unusual complication of melanoma.
|
Oncology (Williston Park)
|
2008
|
0.75
|
|
70
|
A phase II study of Irofulven (MGI 114) in patients with stage IV melanoma.
|
Invest New Drugs
|
2002
|
0.75
|
|
71
|
A young woman with melanoma diagnosed during pregnancy.
|
Oncology (Williston Park)
|
2004
|
0.75
|
|
72
|
A case of Merkel cell carcinoma.
|
Oncology (Williston Park)
|
2008
|
0.75
|